Spruce Biosciences, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -12.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-4.79 | $-6.68 | -39.5% | Miss | |
| Q1 FY26 | $-7.32 | $-8.94 | -22.1% | Miss | |
| Q4 FY25 | $-12.87 | $-9.58 | +25.6% | Beat |
Back to SPRB overview · SPRB holders · SPRB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.